<DOC>
	<DOCNO>NCT02712320</DOCNO>
	<brief_summary>This safety extension 12 month additional treatment LMIS 50 mg subject complete 12 month treatment Protocol FP01C-13-001 remain eligible continued treatment androgen deprivation therapy . Subjects participate Protocol FP01C-13-001-EX follow safety .</brief_summary>
	<brief_title>Open-Label Safety Extension Study Patients Who Have Previously Participated Have Benefited From LMIS 50 mg</brief_title>
	<detailed_description>This multi-center , open-label , single-arm safety extension study . After complete 12 month treatment LMIS 50 mg Protocol FP01C-13-001 ( last dose Protocol FP01C-13-001 approximately 6 month prior Day 0 Protocol FP01C-13-001-EX ) provide write informed consent , subject screen baseline inclusion/exclusion criterion necessary study eligibility . Eligible subject receive LMIS 50 mg prefilled syrinx ( without dilution mix ) two single subcutaneous injection give 6 month apart .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>1 . Complete 12 month treatment LMIS 50 mg Protocol FP01C13001 . If subject wish enter Extension study 28 day follow end study visit Protocol FP01C13001 , serum testosterone level repeat screen visit confirm castratelevel testosterone maintain . 2 . Laboratory value Absolute neutrophil count ≥ 1,500 cells/µL Platelets≥100,000 cells/µL Hemoglobin ≥ 10 gm/dL Total bilirubin ≤ 1.5 × upper limit normal ( ULN ) AST ( SGOT ) ≤ 2.5 × ULN ALT ( SGPT ) ≤ 2.5 × ULN Serum creatinine ≤ 1.5 mg/dL Lipid profile within acceptable range accord investigator 's opinion Serum glucose within acceptable range accord investigator 's opinion HgbA1c within acceptable range accord investigator 's opinion Clinical chemistry ( K , Na , Mg , Ca P ) within acceptable range accord investigator 's judgment Urinalysis within normal range accord investigator 's judgment 3 . Agree use male contraceptive method study trial 4 . In Investigator 's opinion , ability understand nature study hazard participation , communicate satisfactorily Investigator participate , comply , requirement entire protocol 5 . All aspect protocol explain write informed consent obtain *If patient complete 12 month treatment LMIS 50 mg 28 day prior enter Extension study , ECOG , PE , ECG , laboratory PSA test repeat . If patient complete 12 month treatment LMIS 50 mg Protocol FP01C13001 within last 28 day , allow enter Extension study without repeat testosterone measurement , ECG , PE , laboratory PSA test 1 . Receipt chemotherapy , immunotherapy , cryotherapy , radiotherapy , antiandrogen therapy LMIS 50 mg Protocol FP01C13001 treatment carcinoma prostate subject 's participation Protocol FP01C13001 . Radiation pain control allow study . 2 . Receipt LHRH suppressive therapy within 6 month Screening Visit OTHER THAN LMIS 50 mg Protocol FP01C13001 3 . Subject use prohibit treatment list Section 8.2 participation Protocol FP01C13001 . 4 . Any pathological event , clinical adverse event , change subject 's status end FP01C13001 give indication investigator participation study may best interest subject 5 . Investigator considers longer feasible subject include study LMIS 50 mg 6 . Subjects persistent , noncastrate testosterone level judge investigator 7 . Uncontrolled intercurrent illness would jeopardize subject 's safety , interfere objective protocol , limit subject 's compliance study requirement , determine Investigator consultation Sponsor</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Prostate Neoplasm Cancer Carcinoma</keyword>
	<keyword>Safety Extension</keyword>
</DOC>